Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 14;14(11):1155.
doi: 10.3390/antibiotics14111155.

Clinical Impact of Treating Versus Not Treating Asymptomatic Bacteriuria/Candiduria in the First Two Months After Kidney Transplantation

Biagio Pinchera  1 , Rosa Carrano  2 , Isabella Di Filippo  3 , Vincenzo Fotticchia  1 , Mariangela Petrone  1 , Francesco Antimo Alfè  1 , Gianmarco Borriello  2 , Amerigo Piccione  2 , Fabrizio Salemi  2 , Ivan Gentile  1
Affiliations

Clinical Impact of Treating Versus Not Treating Asymptomatic Bacteriuria/Candiduria in the First Two Months After Kidney Transplantation

Biagio Pinchera et al. Antibiotics (Basel). .

Abstract

Background/Objectives: The management of asymptomatic bacteriuria (ASB) and candiduria (ASC) in kidney transplant recipients during the early post-transplant period is controversial. This study aimed to evaluate whether treating, versus not treating, ASB and ASC episodes in the first two months after kidney transplantation influences clinical outcomes and the emergence of multidrug-resistant (MDR) infections. Methods: We conducted a single-center retrospective cohort study enrolling patients with ASB or ASC occurring in the first two months after kidney transplantation between January 2019 and July 2024. Patients were classified into treated and untreated groups. The primary endpoint was 30-day mortality. Secondary endpoints included mortality at 90, 180 and 360 days; incidence of sepsis or septic shock; bacteremia/candidemia, hospitalization, graft loss; decline in renal function, urinary tract infections (UTIs), recurrent UTI and rate of MDR colonization/infection. Results: We enrolled 59 kidney transplant recipients and observed 147 episodes of ASB/ASC. Of the 147 episodes, 95 were untreated and 52 were treated. No significant differences were observed between treated and untreated patients in 30-day (2.1% vs. 3.8%) or 90-day mortality (2.1% vs. 1.9%), nor in any of the secondary clinical outcomes. However, patients who received treatment tended to have a higher rate of MDR colonization/infection (63% vs. 46%). MDR pathogen isolation was significantly associated with increased risks of septic shock (OR 4.639, p = 0.04), bacteremia/candidemia (OR 3.734, p = 0.01), hospitalization (OR 2.183, p = 0.03) and renal function deterioration (OR 3.93, p = 0.03). Conclusions: Antimicrobial treatment of ASB and ASC in the early post-transplant period would seem not to confer clinical benefit and may be associated with the risk of MDR colonization/infection.

Keywords: asymptomatic bacteriuria; asymptomatic candiduria; kidney transplantation; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
90-day survival by treatment group—Kaplan–Meier.
See this image and copyright information in PMC

References

    1. Nicolle L.E., Gupta K., Bradley S.F., Colgan R., DeMuri G.P., Drekonja D., Eckert L.O., Geerlings S.E., Köves B., Hooton T.M., et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2019;68:e83–e110. doi: 10.1093/cid/ciy1121. - DOI - PubMed
    1. Coussement J., Maggiore U., Manuel O., Scemla A., López-Medrano F., Nagler E.V., Aguado J.M., Abramowicz D., European Renal Association-European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) et al. Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: A survey of current practice in Europe. Nephrol. Dial. Transplant. 2018;33:1661–1668. doi: 10.1093/ndt/gfy078. - DOI - PubMed
    1. Goldman J.D., Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant. 2019;33:e13507. doi: 10.1111/ctr.13507. - DOI - PubMed
    1. Coussement J., Kamar N., Matignon M., Weekers L., Scemla A., Giral M., Racapé J., Alamartine É., Mesnard L., Kianda M., et al. Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): A pragmatic, multicentre, randomized, controlled trial. Clin. Microbiol. Infect. 2021;27:398–405. doi: 10.1016/j.cmi.2020.09.005. - DOI - PubMed
    1. Silva J.T., Montoro J., Pérez-Jacoiste Asín M.A., Fernández-Ruiz M., Polanco N., González E., Caro-Teller J.M., Andrés A., Aguado J.M., López-Medrano F. A joint program of antimicrobial stewardship and hospital-acquired infection control to reduce healthcare-associated infections after kidney transplantation: The Hipomenes study. Am. J. Transplant. 2023;23:1949–1960. doi: 10.1016/j.ajt.2023.07.009. - DOI - PubMed

LinkOut - more resources